tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PremiumRatingsKyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position
2M ago
Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
2M ago
Premium
Ratings
Kyverna Therapeutics: Strong Clinical Progress and Regulatory Alignment Support Buy Rating
2M ago
Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley
PremiumThe FlyKyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley
4M ago
Premium
Ratings
Kyverna Therapeutics: Strategic Advancements and Robust Financial Health Underpin Buy Rating
4M ago
Kyverna Therapeutics price target lowered to $12 from $13 at UBS
Premium
The Fly
Kyverna Therapeutics price target lowered to $12 from $13 at UBS
4M ago
PremiumCompany AnnouncementsKyverna Therapeutics Sets 2025 Strategic Priorities for Growth
6M ago
Kyverna Therapeutics announces senior leadership appointments
Premium
The Fly
Kyverna Therapeutics announces senior leadership appointments
7M ago
Premium
Class Action
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100